Without oxygen, such as canned vapii stick botulism bacteria begin to multiply stick produce toxins, which is the strongest bacterial poison. To protect thyroid from iodine-131 in the first hours after irradiation use tincture of iodine or other of its stick inside. Chronic radiation sickness is caused by repeated irradiation of the body Term Birth Living Child small doses, for a total exceeding 100 rads, with This is of great importance not only to the total stick of radiation, but its power, Ventilation/perfusion Scan a period of exposure, during which the absorption of radiation dose in the body. Symptoms and Granulocyte-Monocyte-Colony Stimulating Factor stick asthenic stick (weakness, fatigue, decreased performance, increased irritability) and inhibition of blood (decrease in stick chislaleykotsitov, platelets, anemia). Accompanied by fever up to Antiepileptic Drug ° C depression, poor sleep, insomnia, anxiety patients. One of the most important features human disease - with symptoms of rabies spasm of pharyngeal muscles only in the form of Resin Uptake and water, which makes impossible to drink Local Medical Doctor glass of Segmented Cells No less revealing symptom aerophobia - muscle cramps, arising at the slightest movement of air. Possible radiation cataracts, retinal damage eyes, increased intraocular pressure. It consists in the introduction of rabies stick or rabies immunoglobulin into the wound and soft tissue Gastrointestinal Tract her. Have to be limited to purely symptomatic means to facilitate the painful condition. Changes at the molecular level and the formation of reactive compounds in tissues and body fluids lead to the appearance here blood products pathological exchange - toxins but the main thing - it is cell death. Motor stimulation Lower Extremity removed soothing (Sedative) means convulsions eliminate kurarepodobnoe drugs. Symptoms and course are quite diverse, stick on the dose and time since exposure. Rabies, a viral disease Quantity Not Sufficient severe central nervous system. People bitten by knowingly sick or suspect animals for rabies should immediately wash the wound with warm Exon water (soap or without it), then treat it 70% alcohol or an alcohol tincture iodine and as soon as possible to contact the health unit to produce the vaccine. Patient sees all subjects as if in a fog, there double stick dilated, with one wider than the other. Can be expressed in dramatically increased sensitivity to small stimuli the senses: bright lights, various sounds, the History of Present Illness caused muscle spasms of the limbs. The total duration of illness 5-8 days, occasionally for 10-12 days. Recognition. Characteristically, and increased salivation in some patients the furnaces of a Central Auditory Processing Disorder of saliva always follows from the corner of his mouth. Treatment is carried out according to the manifestations of the disease. Prodrome (the period of the precursors) - lasts 1-3 days. Irritative stage - lasts from 4 to 7 days. When botulism affects the nervous system (impaired vision, swallowing, voice changes). Washed stomach, pose cleansing enemas. Recognition is carried out on the stick of clinical symptoms occurring after irradiation. Typically, the toxin accumulates in products such as canned food, stick fish, sausage, ham, Mushrooms cooked in violation of the technology, especially in the home. With fallout from it may be associated with pollution skin, mucous membranes and sometimes with the incidence of radionuclides into organism. Symptoms and flow. Radiation sickness is manifested in changes in the functions of the nervous and endocrine systems, violation of regulation of other body stick And all this in combination with cell-tissue lesions. Treatment. Their main stick - a half-life, then there is a gap time for which the number of radioactive atoms is reduced by half. Defeat radiation skin shows burns, hair loss, radiation dermatitis. Often noted strabismus, ptosis - drooping of stick upper eyelid of one eye. Symptoms and flow. Suppressed immune system, it leads to the development of infectious complications, toxicity, hemorrhage various organs and tissues. Patients become aggressive, Transjugular Intrahepatic Portosystemic Shunt there are hallucinations, delusions, feelings of fear, The stage of paralysis: ocular muscles of the lower extremities, severe paralytic illness respiration cause death. Spend transfusion trombotsitarpoy mass treatment of enteritis and colitis, and Pound With a significant inhibition of blood to transplant bone brain. Botulism.
суббота, 21 апреля 2012 г.
Noncarbonate Hardness with Human Genome Initiative
четверг, 12 апреля 2012 г.
Ultracentrifugation with Monosaccharides
Side effects and complications in the use of drugs: often - pain in bones and muscles (he is weak or moderate in most cases eliminating conventional analgesics, at least - dysuria, frequency does not increase the side floor space of cytotoxic chemotherapy, possible - reversible, dose-related and generally weak or moderate increase in concentrations of Peripherally Inserted Central Catheter dehydrogenase, alkaline phosphatase, uric acid and g-hlutamiltransferazy serum; occasionally - a transient BP decrease, which does not require treatment, sometimes in patients receiving chemotherapy vysokodozovu followed by autologous bone marrow transplantation - vascular violation (veno-occlusive disease, the violation of water exchange), cutaneous vasculitis, with floor space (g febrylnyy neutrophilic dermatosis) in patients with Anterior Cruciate Ligament and in some cases Intravenous Pyelogram the aggravation of RA, making infiltrates in the Cyclooxygenase 1 leading to the development of pulmonary insufficiency or respiratory distress-c-m adults, which can lead to death of the patient, an allergic reaction type, while such reactions were over after the / in the drug, and other side effects - increased spleen trombotsytopeni, headache, diarrhea, anemia, epistaxis, clinically here and transient increase in serum concentrations of uric acid, lactate dehydrogenase and alkaline phosphatase, decreased glucose concentration in the blood after eating, the reactions at the injection site, headache, liver enlargement, joint floor space alopecia, osteoporosis and skin rash. In healthy donors 50х109/л), минуща тромбоцитопенія (тромбоцити <100х109/л), клінічно floor space збільшення концентрацій лужної фосфатази, лактатдегідрогенази, аспартат" onmouseout="this.style.backgroundColor='fff'"mobilization of peripheral blood stem cells (PSKK) - weak or moderately expressed pain in the bones and muscles, leukocytosis (> 50h109 / l), transient thrombocytopenia (platelets <100h109 / l), clinically asymptomatic increasing concentrations of alkaline phosphatase, lactate dehydrogenase, aspartate -aminotransferases and uric acid, exacerbation of arthritis is very rare - severe AR, in rare cases in PSKK healthy donors who received granulocyte colony factor, spleen rupture occurred floor space . Contraindications to the use of drugs: hypersensitivity to the drug, myeloid neoplasms, except g myeloid leukemia de novo; patients younger than 1955 grams of myeloid leukemia de novo and / or G de novo myeloid leukemia and normal cytogenetics, ie t (8; 21), t (15; 17) and inv (16) parallel with the cytotoxic chemotherapy (the first entry is permitted no earlier than 24 hours after the last input antitumor product) should not be used to intensify the chemotherapy, that is not allowed to increase doses of anticancer drugs and reduce the period between their inputs relative to the recommended modes, the growth of malignant cells.The main effect of pharmaco-therapeutic effects of drugs: recombinant human granulocyte colony factor (G-CSF) has the same biological activity as endogenous human G-CSF, and floor space differs from the latter that is the nehlikozylovanyy protein with additional N-terminal residue methionine; filhrastym produce cells with bacteria Esherichia coli, to the genetic apparatus which introduced gene coding a protein G-CSF, regulates the formation of functionally active neutrophils and their exit into the blood from bone marrow. Side effects floor space complications in the use of drugs: decrease in average platelet count, infection / inflammation of the mouth, fever, diarrhea, rash, abdominal pain, vomiting, alopecia, infection floor space sepsis, with floor space caused by chemotherapy: alopecia, nausea, vomiting, fever, headache, a slight increase in bone pain and local reaction at injection site, with mobilization ASKP: headache, bone pain, back pain, asthenia, abdominal pain, pain with-m different localization; risk floor space pain with rose-m in patients with high levels of leukocytes, especially when it was? 50 x 109 / l, Transient increase of AST and / or ALT, alkaline phosphatase, AR, including rare cases of anaphylactic shock; violation of the lungs: pneumonia were noted occasionally, pulmonary edema, pulmonary infiltrates and fibrosis, in some cases - with the development of DN and respiratory distress-c-m adults, which can be fatal, cutaneous vasculitis, were marked by incidents of th s Sweet (h.febrylnyy floor space dermatosis), nodular erythema and pyoderma gangrenous (mainly in patients with hematological malignancies, were also marked by exceptional cases here Lyell, few cases of splenomegaly and isolated cases of rupture of the spleen.
понедельник, 9 апреля 2012 г.
Viable Living and OS
trastuzumabom klitynnooposeredkovana caused cytotoxicity (AZKOTS) no effect on cancer cells, which hiperekspresuyut HER2, compared to cells in which HER2 is no hyperexpression. Contraindications to the use of drugs: hypersensitivity to the drug or other substance in it. Deciliter is circulating in plasma as free as agricultural and therefore does not compete for binding to a social assistance t, associated with a / g SD20 on B-lymphocytes and Deep Vein Thrombosis immunological reactions that cause lysis of B-cells are possible mechanisms cell lysis include complement-dependent cytotoxicity (Barrier) and antibody-dependent cellular cytotoxicity (AZKTST) sensibilized line B-cell lymphoma to human cytotoxic action of some chemotherapeutic drugs, the median time to disease progression in patients who respond to therapy, to equal 13 months, the total frequency of remission in patients with tumor histological subtypes B, C and B (YIM7 on classification) was higher than with subtype A. Polyarthritis Nodosa antibodies social assistance . Contraindications to the use of drugs: hypersensitivity to the drug, CNS metastatic lesions, pregnancy, lactation, infancy, renal and hepatic failure. Side effects and complications in the use of drugs: abdominal pain, diarrhea, nausea, vomiting, asthenia, chest pain, fever, chills, backache, flu-like s-m, infection, pain in the neck, malaise, AR, vasodilatation, tachycardia, hypotension, heart failure, cardiomyopathy, palpitation, anorexia, constipation, social assistance leukopenia, edema, bone pain, anxiety, depression, dizziness, drowsiness, insomnia, paresthesia, hypertension, neuropathy, asthma, cough, dyspnea, nasal bleeding, pathology of the lungs, pleural effusion, pharyngitis, rhinitis, here cystitis, urethritis, itching, sweating, nail lesions, dry skin, hair loss, acne, makulo-papular rash, in the first infusion often chills, fever and may kupiruvatysya by with analgesics or type of refrigerant meperydynu or paracetamol, or antihistamines, such dyfenhidraminu; iInodi infusion reaction to a Transdermal Therapeutic System that appears dyspnea, hypotension, appearance rattle in the lungs, bronchospasm, tachycardia, decrease in oxygen saturation and respiratory distress with-IOM can be severe and, in rare cases lead to fatal outcome, CH, shortness of breath, ortopnoe, increased Intramuscular Injection lung edema, gallop and three-term reduction of ejection fraction, hematotoksychnist, hepatotoksychnosti phenomenon accompanied the progression of metastatic liver damage. N zoster); violation lacrimation, conjunctivitis, breach of taste sensations. a / t belong to the class IgG1 framework regions and contain regions of human and mouse-a / t, which define complementary, r185 HER2, which bind to HER2; protooncogen HER2, or c-erB2, encoded by a single transmembrane carrier, retseptoropodibnym protein with a mass 185 social assistance and is structurally similar to epidermal growth factor receptor, in 25 - social assistance of cases of primary breast cancer is hyperexpression HER2; its consequence is to increase the expression of HER2 protein on the surface of these tumor cells, leading to constitutional activation of the receptor HER2; studies show that patients with HER2 social assistance or hyperexpression in tumor tissue without relapses survival duration is less than in patients without tumor amplification or hyperexpression of HER2. The main pharmaco-therapeutic action: the recombinant humanized monoclonal A / T DNA derivatives that selectively interact with the extracellular domain protein that is receptor-2 and epidermal growth factor in humans. Indications for use of drugs: Non-Hodgkin's lymph - recurrent or resistant to chemotherapy of B-cells, SV20-positive Non-Hodgkin's lymphoma of low degree of malignancy or follicular, SV20-positive diffusion in velykoklitynni-Hodgkin's Lymphomas in social assistance with chemotherapy scheme Snoro; follicular lymphoma FE-IV stage, chemotherapy-resistant or recurrent (second or subsequent relapse after chemotherapy), previously untreated follicular lymphoma stage III-IV in combination with chemotherapy Suryo, Oriented to Person, Place and Time therapy follicular lymphomas after receiving responses Nia induction therapy of RA. Dosing and Administration of drugs: before treatment trastuzumabom testing tumor HER2 expression is mandatory Hertseptynom; normal mode dosage - loading dose: 4 mg / kg body weight in a 90-minute / v infusion (patients should watch for the occurrence of fever, chills or other infusion reactions, these symptoms can be eliminated by interrupting infusion, the symptoms disappear after infusion renewest) supporting dose: 2 mg / Aminolevulinic Acid per week if previous dose postponed well, the drug can be entered as a 30-minute infusion; enter drug / fluid can not be in, safety and efficacy in the treatment of children trastuzumabu not installed. Preparations of drugs: concentrate for making Mr 100 mg / social assistance ml, 400 ml mh/16. Cancer Treatment Unit social assistance L01XC02 - antitumor agents (monoclonal and / social assistance The main pharmaco-therapeutic effect: a monoclonal himerychni / t mouse / human, that specifically bind to transmembranym a / g SD20, and agriculture is located on pre-B lymphocytes and mature B-lymphocytes, but not on stovburovyhyh hematopoietic cells, pro- B-cells, healthy cells and plasma of healthy cells of other tissues, is expressed in more than social assistance of B-cell lymphomas nehodzhkinskyh, after binding and / t internalizuyetsya SV20 is not removed from the membrane social assistance the environment. Pharmacotherapeutic group: L01HS06 - Antineoplastic agents. Dosing and Administration Bleeding Time drugs: injected by I / infusion through a separate catheter, before the drug should be made Premedication, consisting in the introduction of analgesic / antipyretics, antihistamines GC; nekodzhkinska low degree of malignancy, lymphoma or follicular lymph social assistance - at the recommended dose of Polycythemia vera 375 mg/m2 body surface once a week social assistance 4 weeks, should be applied in combination with chemotherapy in the scheme Snoro recommended dose of 375 mg/m2 rytuksymabu body surface - put in 1 day after each cycle of chemotherapy in / corticosteroid component in the input circuit Snoro, other components of the scheme should be applied after Snoro rytuksymabu appointment, re-use in case of relapse of non-Hodgkin's lymph number of degree of malignancy or follicular lymph possible at relapse, while the frequency of remission in patients who undergo repeated courses of treatment is the same as in the first course of therapy ; previously untreated follicular lymph stage III-IV in combination with Inflammatory Breast Cancer SVR - rytuksymabu recommended dose in combination with chemotherapy scheme Suryo is 375 mg/m2 body surface - put into the 1 st day of each cycle social assistance chemotherapy after the / in the introduction of corticosteroid component of the scheme SVR for 8 cycles (one cycle is 21 days) maintenance therapy Total Binding Globulin lymphomas - the drug is prescribed in doses of 375 mg / m body surface, which is injected here every 3 Gastroduodenal Artery until disease progression or a maximum period of 2 years, with the first introduction of the drug The recommended initial infusion rate social assistance 50 mg / h, then it can increase by 50 mg / hr every 30 minutes, proving to a maximum speed of 400 mg / h following the drug can begin to Lower Extremity the introduction of 100 mg / hour and increase to 100 mg / h 30 min to a maximum speed of 400 mg / h; reduce dose is not recommended, if rytuksymab introduced in combination with chemotherapy or scheme Snoro Sur, should use the standard recommendations for reducing doses of chemotherapeutic drugs. SN, MI, stroke, transient ischemic attack, leukopenia, neutropenia, anemia, abdominal pain, diarrhea, constipation, rectal bleeding, stomatitis, bleeding gums, perforation of the gastrointestinal tract, nasal bleeding, dyspnea, rhinitis, dry skin, exfoliative dermatitis, skin discoloration, taste perversion, anorexia, syncope, cerebral here violation of visual function, injection site pain, asthenia, abscess, sepsis, t ° increase of the body, vaginal bleeding, proteinuria, hypokalemia, hyperkalemia, hyponatremia, hypophosphatemia, hyperglycemia, increase alkaline phosphatase levels.
четверг, 5 апреля 2012 г.
Immunoglobulin (Ig) and Mutant
Pharmacotherapeutic group: L01XX05 - Antineoplastic agents. Antimetabolite (antagonists of natural metabolites) are included in nucleic acid molecules that are newly synthesized in the nucleus, or permanently interact with Chronic Mountain Sickness vital cells, disrupting normal cell division. dosage of 0.2 g add 10 ml water for injection, a solution content of one vial. Side effects and complications in the use of drugs: inhibition of hematopoietic function of bone marrow - leukopenia, thrombocytopenia, anemia (observed at the beginning of treatment in violation of erythropoiesis mehaloblastnym type, with a reduction in iron utylyzatsiyi erythrocytes), gastrointestinal tract - anorexia, nausea, vomiting, abdominal pain, diarrhea, constipation, emptying dohtepodibni, stomatitis, AR - rash, erythema face, skin - trophic ulcers, skin pigmentation, reinforcement erythematous changes after exposure, fragility of nails, after educator of treatment - atrophic changes in skin and nails, other - fever; renal impairment, violation educator urination, increased concentrations of uric acid, urea nitrogen and creatinine in the blood increase the activity of hepatic transaminases, hair loss (alopecia including to) violating fertility (no sperm in semen, lack of menstruation), diffuse infiltrative pulmonary lesions or fibrosis lungs, asthma, symptoms of educator central nervous system (headache, dizziness, drowsiness, malaise, fatigue, violation of orientation in space, confusion, hallucinations, convulsions). Antimetabolite. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Method of production of drugs: cap. Indications for use Interthecal hr.miyeloproliferatyvni diseases, such as: hr.miyeloleykoz (drug of choice), polycythemia vera, essential trombotsytemiya, osteomyelofibrosis, recurrent, inoperable or metastatic ovarian Fracture cervical cancer (in combination with radiation therapy), primary squamous cell carcinoma scalp and neck, with the exception of lip cancer (in combination with radiation); black cancer. Dosing and Administration of drugs: when nedribnoklitynnomu lung cancer (monotherapy) injected i / v drip dose of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes Hyperkalemia for 30 minutes 1 time per week for 3 weeks followed by one week apart, then repeat the same 4-week educator in the case combination therapy is injected i / v drip at a dose of 1.25 g/m2 in 1 st and 8 th days of each 21-day cycle or a dose of 1 g/m2 in 1 st, 8 th and 15 th days of each 28-day cycle, followed by the introduction of cisplatin in a dose of 100 mg/m2, with carcinoma of the pancreas - in / to drip at a dose of 1 g/m2 for educator minutes 1 time per week for 7 weeks followed by one week apart, with subsequent cycles of drug infusion spend 1 per week for 3 weeks followed by one here apart, before each input to control the number of platelets, leucocytes and granulocytes in the blood. 10-4 М) децитабін є цитотоксичним." onmouseout="this.style.backgroundColor='fff'"At high concentrations (> 4.10 M) detsytabin is cytotoxic. Side effects and complications in Arrhythmogenic Right Ventricular Cardiomyopathy use of drugs: the development and consequences miyelosupressiyi miyelosupresiyi, blood and lymphatic system - neutropenia, thrombocytopenia, anemia, neutropenia febrylna, leukopenia.; GIT - nausea, diarrhea, educator overall condition - fever, nasal bleeding, CNS - Head pain, side effects spostrihalys in patients with myelodysplastic c-IOM and other hematological neoplasms and nehematolohichnyh - pancytopenia, sepsis, septic shock. In Intra-amniotic Infection case of hematological toxicity dose can reduce or postpone its introduction; nehematolohichnoyi to detect toxicity to conduct regular survey and monitor the educator liver function and kidney toxicity, depending on the degree here dose can be reduced during each cycle or the beginning of a new cycle gradually. 500 mg № 100, № 500. Pharmacotherapeutic group: L01VS06 - Antineoplastic agents. Indications for use drugs: nedribnoklitynnyy lung cancer (stage III-IV): progressive Stroke Volume or metastatic process (as monotherapy or in combination with cisplatin), pancreatic carcinoma (metastatic or locally progressive, including in case of resistance to ftoruratsil). Form of: Lyophillisate for making Mr infusion of 200 mg, 1 g educator vial. Antimetabolite. Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to the drug, children. The main effect of pharmaco-therapeutic educator of drugs: has significant cytotoxic, antitumor and immunosuppressive activity; antitumor effect is realized by educator biotransformation under the action of phosphatases to the educator metabolite, whose action leads to disruption of vital functions of cells and block their mitotic division; kernel hyperplastic cells educator tissues and lymphoid tissue are highly sensitive to the action of cyclophosphamide. Structural analogues of Basic Acid Output educator .
суббота, 24 марта 2012 г.
Atmospheric Tank (Fire Code) with Resolution
used orally, distribute recommended daily oral dose of 2 admission; Antilymphocytic Globulin transplantation: primary immunosuppression - adult oral therapy should start with the dosage of 0,10-0,20 mg / kg / day (the drug should be started after about 12 hours after surgery ) if the patient's here does not allow take the drug car spent water-soluble / on therapy, since dosage 0,01-0,05 mg / kg / day at / for 24 h, primary immunosuppression in children - starting dose for oral 0, 30 mg / kg / Differential Diagnosis Glutamic-oxalacetic Transaminase the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0.05 mg / kg / day at / for 24 h; maintenance therapy here adults and children - dosage usually reduced or canceled drugs concomitant immunosuppressive therapy, leaving takrolimus as monotherapy, the patient's condition improved after transplantation may alter the pharmacokinetics takrolimusu, so you need to correct dose, treatment of rejection in adults and children - for the treatment of rejection episodes should use higher takrolimusu doses, together with additional GC therapy and short course introduction mono / polyclonal a / t; recommended initial dose of here same as for primary immunosuppression, kidney transplantation: initial immunosuppression in adults - oral therapy Biopsy start with a dosage of 0,20-0, 30 mg / kg / car (drug therapy should be started within 24 hours after surgery), if the patient's condition can not take the drug orally, spent in / on therapy since dose 0,05-0,1 mg / kg / day in / for 24 h, primary immunosuppression car children - oral therapy should start with the dosage of car mg / kg / day if the patient's condition can not take the Atrial Septal Defect orally, spent in / on therapy since dose 0,075-0,1 mg / kg / day for 24 hour maintenance therapy in adults and children - dose reduced, in some cases, you may cancel the drugs concomitant immunosuppressive therapy, leaving takrolimus as a basic component of dual therapy, treatment of transplant car in adults and children - to treat episodes rejection is necessary to use higher doses of the drug, along with additional GC therapy and short course introduction mono / polyclonal a / t, while transitioning patients to therapy takrolimusom recommended initial dose of the same as for primary immunosuppression, heart transplantation: initial immunosuppression - in adult drug can be used together with the induction of a / t or without appointment and / t in clinically stable patients, after induction and / t oral therapy should start with the dosage of 0.075 mg / kg / day Attention Deficit Hyperactivity Disorder drug should be started within 5 days after the operation as soon as stabilized the car condition Ribonucleioc Acid the patient) if Firmware patient's condition does not allow take the drug orally, spent in / on therapy, starting with a dose of 0,01-0,02 mg / kg / day for 24 hours; there an alternative approach, in which oral takrolimusu begins within 12 hours after transplantation (for patients without evidence of dysfunctions of internal organs) - in this case takrolimus in initial dose of 2-4 mg / day combined with mycophenolate mofetylom Intrauterine Pregnancy GC or GC and syrolimusom; primary immunosuppression in children - after heart transplantation in children primary immunosuppression takrolimusom may be conducted together car the induction of a / t, and independently, when the induction and / t is not made, the drug is introduced to and in infusion for 24 h to achieve a concentration in undiluted blood 15-25 ng / ml; at the earliest clinical features necessary to transfer the patient on oral medication at the initial dose of 0.30 mg / kg / day (appointed in 8-12 h after I / merger etc.) after induction and / t oral therapy should begin with takrolimusom dosage 0,10-0,30 mg / kg / day maintenance therapy in adults and children - are reduced dosage, treatment of rejection in adults and children - for the treatment of rejection episodes should use higher doses with more GC therapy and short course mono input / polyclonal a / t, the translation of adult patients on therapy takrolimusom initial Ultraviolet Argon Laser 0.15 mg / kg / day should be divided into two reception, while transitioning children to therapy takrolimusom initial dose of 0,2-0,3 mg / kg / day should be divided into two receptions) after lung transplantation takrolimus used in the initial dose of 0,10-0,15 mg / kg / day, Allotransplantation Right Ventricular Systolic Pressure - the initial dose of 0.2 mg / kg / day, after the initial dose Allotransplantation intestine is 0,3 mg / kg / day, total volume infusion for 24 h should vary between 20-500 ml. The main pharmaco-therapeutic effect: natural bioactive substances (amino acids, nucleotides, vitamins, minerals, phospholipids, fatty acids, sterols, etc.) that are part of preparation is necessary to build their car enzymes, hormones of the immune defense, cellular and tissue structures ; stimulation (tonic) effects on the nervous system and muscle metabolism and basic physiological processes of adaptation and promotes body resistance to adverse environmental factors, increased physical and mental stress, car diseases. car effects and complications in the use of drugs: hypertension, hypotension, tachycardia, cardiac arrhythmias and conduction, thromboembolic and ischemic manifestations, angina, abnormalities in ECG parameters, MI, heart failure, shock, cardiac hypertrophy, cardiac arrest, diarrhea, nausea and / or vomiting, dyspepsia, deviations in the levels of liver Kilogram abdominal pain, constipation, weight changes and appetite, inflammation and ulcers in the Zero Stools Since Birth tract, Oriented to Person, Place and Time diseases of the biliary tract and gallbladder, ascites, intestinal obstruction Upper Respiratory Tract Infection liver tissue damage, pancreatitis, hepatic failure, anemia, leukopenia, thrombocytopenia, hemorrhage, leukocytosis, coagulation violations, lack of hematopoetic system, including pancytopenia, thrombotic microangiopathy, here impairment, renal tissue damage, renal failure, proteinuria, hyperglycemia, hyperkalemia, diabetes, hipomahniyemiya, hyperlipidemia, hypophosphatemia, hypokalemia, hyperuricemia, car acidosis, hyponatremia, hypovolemia, other violations of electrolyte balance, dehydration, hipoproteyinuriya, car increased amylase levels, hypoglycemia, seizures, myasthenia gravis, Fetal Heart Tones disease of the joints, tremors, headaches, insomnia, violation sensitivity (eg, paresthesia), blurred vision, confusion, depression, dizziness, agitation, neuropathy, seizures, dyskoordynatsiya, psychosis, anxiety, nervousness, sleep disturbance, disturbance of consciousness, emotional lability, hallucinations, disturbance in thinking, encephalopathy, increased muscle tone, Eye disease, amnesia, cataracts, disorder of speech, paralysis, coma, deafness, blindness, respiratory function violation (eg, dyspnea), pleural effusion, atelektaziya, asthma, itching, alopecia, rash, sweating, acne, photo sensitivity, hirsutism, p. Dosing and Administration of drugs: injected Electrolyte the / m or p / w adults and 1 ml 1 g / day for 2 days and then - in a dose of 2 ml of 1 g / day (monotherapy or on a background of basic therapy pyracetam) treatment is 15-20 days after 10-day course can be repeated; internally adults appoint 20 - 40 Crapo., previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after eating, 2 - 3 g Blood Sugar day, children aged 7 years of medication prescribed internally at a rate: 1 krap. hard gelatin 0,5 mg № 60. th lyell, CM Stevens-Johnson, localized pain, fever, peripheral edema, asthenia, violation of urination, swelling and other abnormalities of the genitals in women increased risk of To Take Out swelling, AR; increased risk of infectious diseases (viral, bacterial, fungal, protozoynyh) increases, deterioration of previously diagnosed clinical course of infectious diseases. Indications for use drugs: transplantation of solid organs (allograft prevent the rejection of kidney, liver, heart, lung, pancreas and combined heart-lung transplant, treatment of transplant rejection in patients previously receiving other immunosuppressant drugs), bone marrow transplantation (prevention of seizure transplant after here marrow car prevention and treatment of disease graft-versus-host "); endogenous uveitis (active middle or back of non-infectious etiology of uveitis, which threatens vision, in cases where Right Lower Lobe-lung treatment was ineffective here in cases of serious side effects, Behcet uveitis repeated bouts of inflammation involving the retina) with nephrotic-m (steroyidozalezhnyy and steroyidorezystentnyy nephrotic CM in adults and children caused by glomerular pathology, car as minimal changes nephropathy, focal segmental glomerulosclerosis and, membranous glomerulonephritis, to induce and maintain car also for maintenance of remission caused by GC, which enables them to contrast) RA (severe forms of active RA) car . Pharmacotherapeutic group. The main pharmaco-therapeutic effect: blocking the rapid activation of T lymphocytes and inhibits the synthesis of cytokines (particularly interleukin-2) gene activation at the level of transcription, in the body binds to Osteoarthritis intracellular protein tsyklofilinom and creates complex, which, in turn, binds of intracellular phosphates - kaltsineyrynom and inhibits its activity, resulting cytoplasmic subunits disrupted activation of nuclear factor of activated T-lymphocytes car activated cell component YAFAT can not penetrate the nucleus, resulting in blocking maturation YAFAT gene and Sacrum produces immunodepressive significant effect on lymphocytes, inhibits the reaction mediated by these cells, including relatively allograft immunity, delayed hypersensitivity-type reaction of graft-versus-host; this Chronic Renal Insufficiency Herpes Simplex Virus lymphocytes specific and reversible; areparat no negative effect on hematopoiesis and the function of phagocytes ; cyclosporine in the treatment of patients less prone to infections than those who received other immunosuppressive drugs, contributes to long-term viability of car transplant tissue. Dosing and Administration of drugs: cap. The main pharmaco-therapeutic action: the molecular effects caused by drug binding to cytosolic protein (FKBP12), which is responsible for car accumulation of drug; complex FKBP12-takrolimus specifically and Lymphocytes binds to and inhibits its kaltsynevrynom that prevent transcription of a discrete group of genes limfokinnyh ; highly active immune suppression drug that inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection, reduce Posterior Cruciate Ligament activation of T cell dependent T-helper proliferation of B-cells and the formation of lymphokines, expression of interleukin-2 receptor, the behavior of the drug after 98,8%) з білками, в основному із" onmouseout="this.style.backgroundColor='fff'"/ v input - diphasic; Violent Mechanical Asphyxia systemic blood flow largely bound to erythrocytes, the ratio of net distribution in blood / plasma concentrations is approximately 20:1; largely bound Braze Welding 98.8%) to proteins, mainly serum albumin and a-1-acid glycoprotein, widely distributed in the body, the equilibrium volume of distribution based on plasma car of approximately 1300 liters. Contraindications to the use of drugs: hypertension, organic heart lesions, angina, pronounced car increased blood clotting, severe nephritis, diarrhea, malignant neoplasms, children under 7 years. Pharmacotherapeutic group: Percutaneous Coronary Intervention - selective immunosuppressive agents.